MAPK/ERK SIGNALING IN GLIOMAS MODULATES INTERFERON RESPONSES, PROMOTES TUMOR-MICROGLIA CROSSTALK, AND CONFERS SUSCEPTIBILITY TO ANTI-PD-1 AND ANTI-CTLA-4 IMMUNOTHERAPY

被引：0
|
作者：
Kim, Kwang-Soo [1 ]
Zhang, Junyi [2 ]
Dmello, Crismita [1 ]
Grabis, Elena [2 ]
Arrieta, Victor [1 ]
Habashy, Karl [1 ]
Zhao, Junfei [3 ]
Duffy, Joseph [1 ]
Gould, Andrew [1 ]
Chen, Li [1 ]
Balyasnikova, Irina [1 ]
Canoll, Peter [3 ]
Sims, Peter [3 ]
Rabadan, Raul [3 ]
Lee-Chang, Catalina [1 ]
Heiland, Dieter Henrik [2 ]
Sonabend, Adam [1 ]
机构：
[1] Northwestern Univ, Chicago, IL USA
[2] Univ Freiburg, Freiburg, Germany
[3] Columbia Univ, New York, NY USA
来源：
NEURO-ONCOLOGY | 2024年 / 26卷
关键词：
D O I：
10.1093/neuonc/noae165.0274
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
NOAE165.02
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Melanoma tumor microbiome as a predictor of anti-PD-1 and anti-CTLA-4 immunotherapy response
    Uzelac, Matthew
    Li, Wei Tse
    Li, Yuxiang
    Ongkeko, Weg M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Predictive biomarkers for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
    Subrahmanyam, Priyanka
    Dong, Zhiwan
    Gusenleitner, Daniel
    Giobbie-Hurder, Anita
    Severgnini, Mariano
    Zhou, Jun
    Manos, Michael
    Maecker, Holden
    Hodi, F. Stephen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [3] CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients
    Goltz, Diane
    Gevensleben, Heidrun
    Vogt, Timo J.
    Dietrich, Joern
    Golletz, Carsten
    Bootz, Friedrich
    Kristiansen, Glen
    Landsberg, Jennifer
    Dietrich, Dimo
    JCI INSIGHT, 2018, 3 (13):
  • [4] Combination immunotherapy using anti-PD-1/PD-L1 plus anti-CTLA-4 antibodies
    Reck, Martin
    ANNALS OF ONCOLOGY, 2021, 32 : S249 - S249
  • [5] Tumor eradication in a murine model of glioma with vaccination and anti-CTLA-4 but not anti-PD-1
    Field, Cameron S.
    Hunn, Martin K.
    Ferguson, Peter M.
    Yagita, Hideo
    Hermans, Ian F.
    Ancelet, Lindsay R.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [6] Anti-PD-1, Anti-PD-L1 and Anti-CTLA-4 checkpoint inhibitor treatment leads to different responses in syngeneic tumor models
    Jantscheff, Peter
    Schaefer-Obodozie, Cynthia
    Moor, Sandra
    Weber, Holger
    CANCER RESEARCH, 2016, 76
  • [7] Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
    Subrahmanyam, Priyanka B.
    Dong, Zhiwan
    Gusenleitner, Daniel
    Giobbie-Hurder, Anita
    Severgnini, Mariano
    Zhou, Jun
    Manos, Michael
    Eastman, Lauren M.
    Maecker, Holden T.
    Hodi, F. Stephen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [8] Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy
    Rogiers, Aljosja
    Dimitriou, Florentia
    Lobon, Irene
    Harvey, Catriona
    Vergara, Ismael A.
    da Silva, Ines Pires
    Lo, Serigne N.
    Scolyer, Richard A.
    Carlino, Matteo S.
    Menzies, Alexander M.
    Long, Georgina V.
    EUROPEAN JOURNAL OF CANCER, 2024, 198
  • [9] Activity of Anti-PD-1 in Murine Tumor Models: Role of "Host" PD-L1 and Synergistic Effect of Anti-PD-1 and Anti-CTLA-4
    Korman, Alan
    Chen, Bing
    Wang, Changyu
    Wu, Linda
    Cardarelli, Pina
    Selby, Mark
    JOURNAL OF IMMUNOLOGY, 2007, 178
  • [10] Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies
    Kudo, Masatoshi
    LIVER CANCER, 2019, 8 (06) : 413 - 426
12345